“Bendamustine Is a Hybrid Antimetabolite and Alkylating Agent Offering New Therapeutic Options for the Treatment of Non-Hodgkin Lymphomas”. Hematology Meeting Reports 2, no. 5 (June 23, 2009). Accessed July 14, 2026. https://journals.pagepress.net/hmr/article/view/749.